More recently, a shRNA strategy has been used to silence TGF-β1 in lymphoma cells, forcing them to release TGF-β1-depleted EV, thus removing a strong antitumor–immune surveillance inhibitor and increasing the response of the immune system against leukemic cells (91). This evidence concerns the gene TGFB1 and lymphoma.